康拓医疗(688314) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥71,474,720.87, representing a year-over-year increase of 13.30%[5] - The net profit attributable to shareholders for Q3 2023 was ¥25,166,508.55, showing a slight decrease of 2.29% compared to the same period last year[5] - The basic earnings per share for Q3 2023 was ¥0.31, down by 3.13% year-over-year[6] - Total operating revenue for the first three quarters of 2023 reached ¥206,601,313.31, an increase of 15.73% compared to ¥178,480,246.74 in the same period of 2022[18] - Net profit for Q3 2023 was ¥63,644,004.61, slightly down from ¥63,734,398.66 in Q3 2022, representing a decrease of 0.14%[20] - Earnings per share for Q3 2023 was ¥0.79, compared to ¥0.80 in Q3 2022, reflecting a decrease of 1.25%[21] - The company reported a total comprehensive income of ¥63,747,533.26 in Q3 2023, down from ¥65,449,832.96 in Q3 2022, a decrease of 2.60%[21] Research and Development - Research and development expenses totaled ¥5,458,986.56 in Q3 2023, accounting for 7.64% of operating revenue, a decrease of 0.47 percentage points from the previous year[6] - Research and development expenses for Q3 2023 were ¥13,734,653.11, up 23.56% from ¥11,122,398.10 in Q3 2022[19] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥653,557,852.75, reflecting a 2.42% increase from the end of the previous year[6] - The company's current assets totaled RMB 410,562,064.39, slightly up from RMB 404,318,862.81 in the previous year, indicating a growth of about 1.2%[15] - The company's non-current assets totaled RMB 242,995,788.36, an increase from RMB 233,816,881.07, indicating a growth of approximately 3.1%[16] - Total liabilities decreased to RMB 71,907,287.66 from RMB 87,631,814.91, representing a reduction of about 18.0%[16] - The company's accounts payable decreased significantly from RMB 19,288,782.14 to RMB 11,267,121.05, a decline of approximately 41.7%[16] - The total liabilities decreased to ¥79,297,692.68 in Q3 2023 from ¥96,462,236.78 in Q3 2022, a reduction of 17.83%[19] Cash Flow - The company reported a cash flow from operating activities of ¥64,742,464.57 year-to-date, which is a decrease of 13.60% compared to the previous year[6] - Cash inflow from operating activities for the first three quarters of 2023 totaled ¥251,458,415.59, an increase of 19.37% from ¥210,741,748.56 in the same period of 2022[22] - The net cash flow from operating activities for Q3 2023 was CNY 64,742,464.57, a decrease of 13.4% compared to CNY 74,932,246.33 in Q3 2022[24] - The net cash flow from investing activities was -CNY 148,917,105.95, worsening from -CNY 114,685,668.05 year-over-year[24] - The net cash flow from financing activities was -CNY 30,628,196.86, compared to -CNY 37,117,293.41 in the same quarter last year, indicating an improvement[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,941[12] - The largest shareholder, Hu Liren, holds 39,435,788 shares, representing 48.54% of the total shares[12] - The company reported a total of 335,290 shares held by Shenzhen Qianhai Daoming Investment Management Co., Ltd. through various accounts[13] Government Support and Taxation - The company received government subsidies amounting to ¥2,494,781.25 during the reporting period, contributing to its non-operating income[8] - Tax payments rose significantly to CNY 45,387,774.67 in Q3 2023 from CNY 22,526,765.47 in the same period last year, marking a 101.5% increase[24] Employee Compensation - The company paid CNY 51,616,821.83 in employee compensation during Q3 2023, up from CNY 44,981,069.23 in Q3 2022, representing a 14.5% increase[24] Strategic Developments - The company has not disclosed any significant new strategies or product developments during the reporting period[14]